4.6 Review

Progress in Translational Regulatory T Cell Therapies for Type 1 Diabetes and Islet Transplantation

Journal

ENDOCRINE REVIEWS
Volume 42, Issue 2, Pages 198-218

Publisher

ENDOCRINE SOC
DOI: 10.1210/endrev/bnaa028

Keywords

type 1 diabetes; islet; transplantation; regulatory T cells; tolerance

Funding

  1. Patronato del Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
  2. Fundacion para la Salud y la Educacion
  3. Alberta Health Services
  4. Juvenile Diabetes Research Foundation International (JDRF)
  5. Juvenile Diabetes Research Foundation Canadian Clinical Trials Network (JDRF CCTN)
  6. Liana's Dream Foundation
  7. Diabetes Research Institute Foundation Canada (DRIFCan).

Ask authors/readers for more resources

Regulatory T cells (Tregs) are important in the pathophysiology and treatment of autoimmune diseases like type 1 diabetes (T1D) and have shown potential in transplantation as well. Modulating the quantity and function of Tregs can increase self-tolerance and provide a potential cure for diseases. Islet transplantation serves as a critical approach to study the interplay between autoimmunity and transplantation immunity, offering a potential cure for T1D.
Regulatory T cells (Tregs) have become highly relevant in the pathophysiology and treatment of autoimmune diseases, such as type 1 diabetes (T1D). As these cells are known to be defective in T1D, recent efforts have explored ex vivo and in vivo Treg expansion and enhancement as a means for restoring self-tolerance in this disease. Given their capacity to also modulate alloimmune responses, studies using Treg-based therapies have recently been undertaken in transplantation. Islet transplantation provides a unique opportunity to study the critical immunological crossroads between auto- and alloimmunity. This procedure has advanced greatly in recent years, and reports of complete abrogation of severe hypoglycemia and long-term insulin independence have become increasingly reported. It is clear that cellular transplantation has the potential to be a true cure in T1D, provided the remaining barriers of cell supply and abrogated need for immune suppression can be overcome. However, the role that Tregs play in islet transplantation remains to be defined. Herein, we synthesize the progress and current state of Treg-based therapies in T1D and islet transplantation. We provide an extensive, but concise, background to understand the physiology and function of these cells and discuss the clinical evidence supporting potency and potential Treg-based therapies in the context of T1D and islet transplantation. Finally, we discuss some areas of opportunity and potential research avenues to guide effective future clinical application. This review provides a basic framework of knowledge for clinicians and researchers involved in the care of patients with T1D and islet transplantation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available